About the Event
Every year, millions of device implant patients are affected by hospital-associated infections (HAIs) resulting in increased deaths and billions of dollars in unnecessary hospital costs.
Orthobond has solved this problem by creating a covalently bound nanosurface that kills bacteria, viruses and fungi on any surface without using antibiotics. There are broad applications in the medical industry, with the company’s initial focus the $1B orthopedic oncology market and $2.7B spinal pedicle screw market. There is also significant opportunity in commercial, industrial, and automotive markets.
Please join our webinar with Orthobond CEO, David L. Nichols, as he provides details on their game-changing technology and the company’s plans to commercialize it in a number of markets.